Cibus Q2 FY26 net loss narrows 17% to $22.1 million; revenue rises 6.54% to $994,000
CBUS•Cash position and program updates
Cash and cash equivalents totaled $20.4 million at June 30; existing cash is expected to fund operations into early Q1 2027.
Rice herbicide-tolerance programs advanced in field trials; Interoc LOI expanded from two traits to five, with 2028 LATAM launch targets.
CEO Craig Wichner said priorities are shifting toward near-term revenue, citing a patent portfolio of more than 500 filings.
Q2 revenue rises as net loss narrows
Cibus posted Q2 revenue of $994,000, up 6.54% year over year; net loss narrowed to $22.1 million from $26.6 million.
R&D expense fell 30.27% to $8.5 million; SG&A dropped 18.79% to $5.4 million, both due to cost reduction initiatives.
